2026 Q2 -tulosraportti
Vain PDF
18 päivää sitten
7,00 DKK/osake
Viimeisin osinko
1,76%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
10 188
Myynti
Määrä
18 476
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 162 | - | - | ||
| 8 | - | - | ||
| 8 | - | - | ||
| 2 | - | - | ||
| 59 | - | - |
Ylin
402,8VWAP
Alin
395,4VaihtoMäärä
26,9 67 622
VWAP
Ylin
402,8Alin
395,4VaihtoMäärä
26,9 67 622
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 | ||
2025 Q2 -tulosraportti 5.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·14 t sittenWith an EPS of 10,70 kr. last year (PE 40) and an expectation of over 12 kr. this year, you are currently paying around 32 times this year's expected earnings (at a price of 400). That is at the lower end of what ChemoMetec has historically been traded at. Expectations for EPS in 2028 are 19 kr, which will give a PE of 20 at a price of 400. Personally, I believe that chemometec's growth journey continues and I am happy to pay a premium to join in. In my opinion, the "upside" (potential for a price of 700-800 in 2028) is significantly greater than the "downside", but it requires ChemoMetec to succeed and deliver on their strategy. I have bought ChemoMetec with a long time horizon - at least until 2028, and try to disregard "noise" from shutdowns in the USA, tariffs etc. even though it is difficult. Technically, I hope that the price stays around the support here at 400 kr, and then slowly climbs up towards the next financial report. If the price goes down to test the support around 330, then I consider adding to my position. This is not a buy recommendation, but an elaboration on my previous comment to @Toby1970, as well as a reply to @JanRou
·8 t sittenYes, I have also made thorough PEG calculations up to 2028. And they all look reasonable, at the current price of around 400. It is typically said that companies with PEG around 1 are well-priced for their growth, or slightly above can be accepted depending on the situation. The earnings growth rates are around 20-30% annually, which gives a PEG of approx. 1,5 through the years up to 2028. A bit on the high side, but these are after all conservative expectations. Trump is the big player creating uncertainty, but the midterm elections in the USA are coming soon. He will lose support there, and a more stable world will probably be created. Growth at Chemometec can therefore become greater and more predictable, given that USA/Canada is their largest market.
·1 päivä sittenUp or down?? What does your gut feeling say:)
·18 t sitten · MuokattuI see two scenarios until the next financial report, both unfortunately pessimistic, unless unexpected good news arrives before the report: 1) The price holds the level 400 +-3% i.e. p/e~40 2) The price steadily falls towards p/e ~30 i.e. price 325 Ps. I wouldn't spend my time analyzing arbitrary numbers. Instead, I would look at interesting sectors for the future.
·3 päivää sittenShould one place an order now?
·1 päivä sittenAgreed. I hardly ever daytrade. A swing trade in a stock I am long in can make sense. There's just a sell order with some profit, if it sells, then fine. It would perhaps be 20 % of my position that I put up for sale.
·3 päivää sitten · MuokattuShort is now 0,93% https://www.zirium.dk/short-watch-details?code=DK0060055861- ·16.2.H1 figures give a picture of a stock that needs to go further down. H1 eps= 5,4 ~ full-year eps ~ 11. If we are to achieve a P/E <30, the share price must go down to <330. Return also does not paint a good picture: eps growth <3% (10,7->11), dividend 7 (historical) ~1,8% and no share buyback gives a "return of <4,8%. What am I missing?·16.2.@Toby1970 Here are the primary things your calculation does not account for: - Temporary dip in the USA: The decline is primarily due to a "sharp slowdown" caused by the US government shutdown at the end of 2025, which cost approx. 20 mio. kr. in revenue in November alone. - Maintenance of guidance: Despite a weak EPS in H1, management maintains the annual expectations of an EBITDA of 320-335 mio. kr. They therefore expect to recover the lost ground in H2. -New growth engines: The new XcytoMatic-platform is growing by 60%, and the fresh partnership with Roche Diagnostics (Feb. 2026) is seen as a massive future trigger. - EBITDA margin of 55%. The margin increased compared to the same period last year (1st half 2024/25), where it was 53,8%. This is a company with strong pricing power - Insider buying: Chairman of the Board Niels Thestrup has utilized the share price drop in February to buy additional shares, which signals confidence in a turnaround. Conclusion: Your calculation is correct based on the current figures, but you overlook the possibility for future growth (Roche and the H2 recovery) that exists in the company. Have bought my first shares in ChemoMetec today based on the above. #no buy recommendation
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
Vain PDF
18 päivää sitten
7,00 DKK/osake
Viimeisin osinko
1,76%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·14 t sittenWith an EPS of 10,70 kr. last year (PE 40) and an expectation of over 12 kr. this year, you are currently paying around 32 times this year's expected earnings (at a price of 400). That is at the lower end of what ChemoMetec has historically been traded at. Expectations for EPS in 2028 are 19 kr, which will give a PE of 20 at a price of 400. Personally, I believe that chemometec's growth journey continues and I am happy to pay a premium to join in. In my opinion, the "upside" (potential for a price of 700-800 in 2028) is significantly greater than the "downside", but it requires ChemoMetec to succeed and deliver on their strategy. I have bought ChemoMetec with a long time horizon - at least until 2028, and try to disregard "noise" from shutdowns in the USA, tariffs etc. even though it is difficult. Technically, I hope that the price stays around the support here at 400 kr, and then slowly climbs up towards the next financial report. If the price goes down to test the support around 330, then I consider adding to my position. This is not a buy recommendation, but an elaboration on my previous comment to @Toby1970, as well as a reply to @JanRou·8 t sittenYes, I have also made thorough PEG calculations up to 2028. And they all look reasonable, at the current price of around 400. It is typically said that companies with PEG around 1 are well-priced for their growth, or slightly above can be accepted depending on the situation. The earnings growth rates are around 20-30% annually, which gives a PEG of approx. 1,5 through the years up to 2028. A bit on the high side, but these are after all conservative expectations. Trump is the big player creating uncertainty, but the midterm elections in the USA are coming soon. He will lose support there, and a more stable world will probably be created. Growth at Chemometec can therefore become greater and more predictable, given that USA/Canada is their largest market.
- ·1 päivä sittenUp or down?? What does your gut feeling say:)·18 t sitten · MuokattuI see two scenarios until the next financial report, both unfortunately pessimistic, unless unexpected good news arrives before the report: 1) The price holds the level 400 +-3% i.e. p/e~40 2) The price steadily falls towards p/e ~30 i.e. price 325 Ps. I wouldn't spend my time analyzing arbitrary numbers. Instead, I would look at interesting sectors for the future.
- ·3 päivää sittenShould one place an order now?·1 päivä sittenAgreed. I hardly ever daytrade. A swing trade in a stock I am long in can make sense. There's just a sell order with some profit, if it sells, then fine. It would perhaps be 20 % of my position that I put up for sale.
- ·3 päivää sitten · MuokattuShort is now 0,93% https://www.zirium.dk/short-watch-details?code=DK0060055861
- ·16.2.H1 figures give a picture of a stock that needs to go further down. H1 eps= 5,4 ~ full-year eps ~ 11. If we are to achieve a P/E <30, the share price must go down to <330. Return also does not paint a good picture: eps growth <3% (10,7->11), dividend 7 (historical) ~1,8% and no share buyback gives a "return of <4,8%. What am I missing?·16.2.@Toby1970 Here are the primary things your calculation does not account for: - Temporary dip in the USA: The decline is primarily due to a "sharp slowdown" caused by the US government shutdown at the end of 2025, which cost approx. 20 mio. kr. in revenue in November alone. - Maintenance of guidance: Despite a weak EPS in H1, management maintains the annual expectations of an EBITDA of 320-335 mio. kr. They therefore expect to recover the lost ground in H2. -New growth engines: The new XcytoMatic-platform is growing by 60%, and the fresh partnership with Roche Diagnostics (Feb. 2026) is seen as a massive future trigger. - EBITDA margin of 55%. The margin increased compared to the same period last year (1st half 2024/25), where it was 53,8%. This is a company with strong pricing power - Insider buying: Chairman of the Board Niels Thestrup has utilized the share price drop in February to buy additional shares, which signals confidence in a turnaround. Conclusion: Your calculation is correct based on the current figures, but you overlook the possibility for future growth (Roche and the H2 recovery) that exists in the company. Have bought my first shares in ChemoMetec today based on the above. #no buy recommendation
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
10 188
Myynti
Määrä
18 476
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 162 | - | - | ||
| 8 | - | - | ||
| 8 | - | - | ||
| 2 | - | - | ||
| 59 | - | - |
Ylin
402,8VWAP
Alin
395,4VaihtoMäärä
26,9 67 622
VWAP
Ylin
402,8Alin
395,4VaihtoMäärä
26,9 67 622
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 | ||
2025 Q2 -tulosraportti 5.2.2025 |
2026 Q2 -tulosraportti
Vain PDF
18 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 | ||
2025 Q2 -tulosraportti 5.2.2025 |
7,00 DKK/osake
Viimeisin osinko
1,76%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·14 t sittenWith an EPS of 10,70 kr. last year (PE 40) and an expectation of over 12 kr. this year, you are currently paying around 32 times this year's expected earnings (at a price of 400). That is at the lower end of what ChemoMetec has historically been traded at. Expectations for EPS in 2028 are 19 kr, which will give a PE of 20 at a price of 400. Personally, I believe that chemometec's growth journey continues and I am happy to pay a premium to join in. In my opinion, the "upside" (potential for a price of 700-800 in 2028) is significantly greater than the "downside", but it requires ChemoMetec to succeed and deliver on their strategy. I have bought ChemoMetec with a long time horizon - at least until 2028, and try to disregard "noise" from shutdowns in the USA, tariffs etc. even though it is difficult. Technically, I hope that the price stays around the support here at 400 kr, and then slowly climbs up towards the next financial report. If the price goes down to test the support around 330, then I consider adding to my position. This is not a buy recommendation, but an elaboration on my previous comment to @Toby1970, as well as a reply to @JanRou·8 t sittenYes, I have also made thorough PEG calculations up to 2028. And they all look reasonable, at the current price of around 400. It is typically said that companies with PEG around 1 are well-priced for their growth, or slightly above can be accepted depending on the situation. The earnings growth rates are around 20-30% annually, which gives a PEG of approx. 1,5 through the years up to 2028. A bit on the high side, but these are after all conservative expectations. Trump is the big player creating uncertainty, but the midterm elections in the USA are coming soon. He will lose support there, and a more stable world will probably be created. Growth at Chemometec can therefore become greater and more predictable, given that USA/Canada is their largest market.
- ·1 päivä sittenUp or down?? What does your gut feeling say:)·18 t sitten · MuokattuI see two scenarios until the next financial report, both unfortunately pessimistic, unless unexpected good news arrives before the report: 1) The price holds the level 400 +-3% i.e. p/e~40 2) The price steadily falls towards p/e ~30 i.e. price 325 Ps. I wouldn't spend my time analyzing arbitrary numbers. Instead, I would look at interesting sectors for the future.
- ·3 päivää sittenShould one place an order now?·1 päivä sittenAgreed. I hardly ever daytrade. A swing trade in a stock I am long in can make sense. There's just a sell order with some profit, if it sells, then fine. It would perhaps be 20 % of my position that I put up for sale.
- ·3 päivää sitten · MuokattuShort is now 0,93% https://www.zirium.dk/short-watch-details?code=DK0060055861
- ·16.2.H1 figures give a picture of a stock that needs to go further down. H1 eps= 5,4 ~ full-year eps ~ 11. If we are to achieve a P/E <30, the share price must go down to <330. Return also does not paint a good picture: eps growth <3% (10,7->11), dividend 7 (historical) ~1,8% and no share buyback gives a "return of <4,8%. What am I missing?·16.2.@Toby1970 Here are the primary things your calculation does not account for: - Temporary dip in the USA: The decline is primarily due to a "sharp slowdown" caused by the US government shutdown at the end of 2025, which cost approx. 20 mio. kr. in revenue in November alone. - Maintenance of guidance: Despite a weak EPS in H1, management maintains the annual expectations of an EBITDA of 320-335 mio. kr. They therefore expect to recover the lost ground in H2. -New growth engines: The new XcytoMatic-platform is growing by 60%, and the fresh partnership with Roche Diagnostics (Feb. 2026) is seen as a massive future trigger. - EBITDA margin of 55%. The margin increased compared to the same period last year (1st half 2024/25), where it was 53,8%. This is a company with strong pricing power - Insider buying: Chairman of the Board Niels Thestrup has utilized the share price drop in February to buy additional shares, which signals confidence in a turnaround. Conclusion: Your calculation is correct based on the current figures, but you overlook the possibility for future growth (Roche and the H2 recovery) that exists in the company. Have bought my first shares in ChemoMetec today based on the above. #no buy recommendation
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
10 188
Myynti
Määrä
18 476
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 162 | - | - | ||
| 8 | - | - | ||
| 8 | - | - | ||
| 2 | - | - | ||
| 59 | - | - |
Ylin
402,8VWAP
Alin
395,4VaihtoMäärä
26,9 67 622
VWAP
Ylin
402,8Alin
395,4VaihtoMäärä
26,9 67 622
Välittäjätilasto
Dataa ei löytynyt